Comparative Study of CTD Modules 3, 4, and 5: Generic Drugs versus Complex Generics (Liposomal Injectables) in the United States, European Union, and Japan
International Journal of Drug Regulatory Affairs · 15.06.2026 · 14 (2) · 49-53
DOI: 10.22270/ijdra.v14i2.889 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Drug Regulatory Affairs, online erschienen am 15.06.2026. Verfasst von Manasvi Kotadia und 5 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Liposomal drug delivery systems form an important branch of pharmaceutical product nanomedicine. Unlike traditional small-molecule generics, structural and physicochemical characteristics of a lipid carrier system do not only regulate the therapeutic behavior of an active pharmaceutical ingredient but also influence it. The liposomal formulations are therefore categorised as complex generics or non-biological complex drugs (NBCDs). To prove the similarity of liposomal generics and their reference products would thus require a wider range of analytical, non-clinical and clinical data in comparison with traditional generics. The current paper compares liposomal complex generics regulatory expectations in 3 major jurisdictions of the United States, the European Union, and Japan. The comparison will be made on the Common Technical Document(CTD) Modules 3, 4, and 5, which indicate, quality documentation, non-clinical evidence, and clinical evidence respectively. Regulations and peer-reviewed literature have been analyzed in order to determine variation in regulatory demands across these areas. The results show that complex generics require thorough description of physicochemical properties, biological activity as well as pharmacokinetic functioning due to the impact of nanoscale structural features on drug targeting and toxicity. Regulatory agencies vary in their scientific principles even though they have similar principles of regulation. European Union is focused on comparability in detail; Japan focuses more on mechanistic non-clinical evaluation and the United States uses a risk-based regulatory model which incorporates quality attributes and pharmacokinetic data. These regulatory differences can help pharmaceutical developers to understand before submitting liposomal complex generics to global regulations. Conclusion:Liposomal generics require more extensive evaluation than traditional generics, including detailed structural and biological characterization. Regulatory expectations differ: Europe emphasizes analytical comparability, Japan focuses on nonclinical studies, and the US follows a risk-based approach with quality and PK data. Understanding these regional differences is essential for efficient development and successful global submissions.
Zitieren
APA
Kotadia, M., Movaliya, V., Kanaki, N., Zaveri, M., Khacharia, S., & Patel, Z. (2026). Comparative Study of CTD Modules 3, 4, and 5: Generic Drugs versus Complex Generics (Liposomal Injectables) in the United States, European Union, and Japan. International Journal of Drug Regulatory Affairs, 14(2), 49-53. https://doi.org/10.22270/ijdra.v14i2.889
Vancouver
Kotadia M, Movaliya V, Kanaki N, Zaveri M, Khacharia S, Patel Z. Comparative Study of CTD Modules 3, 4, and 5: Generic Drugs versus Complex Generics (Liposomal Injectables) in the United States, European Union, and Japan. International Journal of Drug Regulatory Affairs. 2026;14(2):49-53. doi:10.22270/ijdra.v14i2.889
BibTeX
@article{Kotadia2026,
author = {Kotadia, Manasvi and Movaliya, Vinit and Kanaki, Niranjan and Zaveri, Maitreyi and Khacharia, Shailesh and Patel, Zuki},
title = {Comparative Study of CTD Modules 3, 4, and 5: Generic Drugs versus Complex Generics (Liposomal Injectables) in the United States, European Union, and Japan},
journal = {International Journal of Drug Regulatory Affairs},
year = {2026},
volume = {14},
number = {2},
pages = {49--53},
doi = {10.22270/ijdra.v14i2.889}
}
EUVIMED